Header Logo

Connection

WEN-JEN HWU to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications WEN-JEN HWU has written about Dose-Response Relationship, Drug.
WEN-JEN HWU
Connection Strength
0.327
Dose-Response Relationship, Drug
  1. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res. 2010 Dec; 20(6):501-6.
    View in: PubMed
    Score: 0.054
  2. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003 Sep 01; 21(17):3351-6.
    View in: PubMed
    Score: 0.032
  3. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol. 2002 Jun 01; 20(11):2610-5.
    View in: PubMed
    Score: 0.030
  4. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018 02 22; 3(4).
    View in: PubMed
    Score: 0.022
  5. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017 09; 18(9):1202-1210.
    View in: PubMed
    Score: 0.021
  6. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015 Nov; 51(17):2689-97.
    View in: PubMed
    Score: 0.019
  7. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma. Melanoma Res. 2014 Aug; 24(4):342-8.
    View in: PubMed
    Score: 0.017
  8. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17.
    View in: PubMed
    Score: 0.017
  9. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44.
    View in: PubMed
    Score: 0.016
  10. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther. 2012 Aug; 12(8):1087-99.
    View in: PubMed
    Score: 0.015
  11. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28; 366(26):2455-65.
    View in: PubMed
    Score: 0.015
  12. Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer. 2012 Oct; 20(10):2583-8.
    View in: PubMed
    Score: 0.014
  13. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon a-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2011 Mar; 67(3):657-66.
    View in: PubMed
    Score: 0.013
  14. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
    View in: PubMed
    Score: 0.012
  15. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2009 Jun; 64(1):161-7.
    View in: PubMed
    Score: 0.012
  16. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007 May 20; 25(15):2078-85.
    View in: PubMed
    Score: 0.010
  17. Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res. 2003 Apr; 13(2):189-96.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.